According to a study published in Cancer Research, the injectable contraceptive, Depo-Provera, can double the risk of invasive breast cancer in young women.
New York, New York (PRWEB) April 09, 2012
Parker Waichman LLP, a national law firm representing victims of defective drugs and medical devices, is evaluating potential lawsuit claims related to Depo-Provera (depo-medroxyprogesterone acetate or DMPA) and breast cancer. The birth control shots, which are given once every three months, prevent pregnancy solely through progestin; many other contraceptives incorporate a progestin-estrogen combination. According to a new study published in the April 15th issue of Cancer Research, the injectable contraceptive can double the risk of invasive breast cancer in young women. [cancerres.aacrjournals.org/content/early/2012/02/25/0008-5472.CAN-11-4064.abstract?sid=b94f53d7-cd3e-4624-af50-5a8b0a5cc970]
This is not the first time Depo-Provera has been associated with an increased risk of breast cancer. According to the Cancer Research study, the contraceptives shot contains the same progestin as the menopausal hormone therapy regimen found to increase breast cancer risk among postmenopausal women in the Women's Health Initiative clinical trial. Lead researcher on the Cancer Research study and breast cancer epidemiologist Christopher I. Li M.D., Ph.D, of the Fred Hutchinson Cancer Research Center, also notes that multiple studies involving young women and DPMA have produced mixed findings. "Our study adds to the body of knowledge from international studies conducted in a diverse group of countries – Kenya, New Zealand, Thailand, Mexico and Costa Rica – which have shown that one of the risks associated with DMPA use may be an increased risk of breast cancer," Dr. Li said in a press release issued by the Fred Hutchinson Cancer Center. Dr. Li’s study is the first major U.S. based study showing that Depo-Provera can also pose this danger to younger women; his team studied nearly 2,000 women between the ages of 20 to 44, the release said. [fhcrc.org/content/public/en/news/releases/2012/04/dmpa-breast-cancer-risk-chris-li.html]
Depo-Provera has also been linked to other serious side effects, such as bone loss. The risks associated with the injectable birth control appeared so severe that the FDA has advised it as a last resort, stating that “Depo-Provera Contraceptive should be used as a long-term birth control method (eg, longer than 2 years) only if other birth control methods are inadequate.” [fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154784.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=depo-provera&utm_content=1]
The new study, however, shows that the risk of breast cancer in young women can increase 2.2-fold after only one year. The study also found that the risk seemed to decline months after women stopped taking Depo-Provera, which only strengthens the correlation. Li’s findings echo the FDA’s cautioning advice about Depo-Provera. “In the United States many women have numerous options for contraception, and so it is important to balance their risks and benefits when making contraceptive choices” Dr. Li said, according to the statement from the Fred Hutchinson Cancer Center.
Parker Waichman LLP offers free legal consultations to breast cancer patients attributing their diagnosis to Depo-Provera. If you or a loved one were diagnosed with breast cancer and you believe it to be a result of Depo-Provera injections, please contact their office by visiting the firm's at Depo-Provera page http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
For more information regarding Depo-Provera breast cancer lawsuits and Parker Waichman LLP, please visit: http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Contact: Parker Waichman LLP
Herbert Waichman, Partner